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Abstract
Background: Chronic Helicobacter pylori infection plays a central role in the development of gastric cancer as shown by
biological and epidemiological studies. The H. pylori antibody and serum pepsinogen (PG) tests have been anticipated to
predict gastric cancer development.
Methods: We determined the predictive sensitivity and specificity of gastric cancer development using these
tests. Receiver operating characteristic analysis was performed, and areas under the curve were estimated. The
predictive sensitivity and specificity of gastric cancer development were compared among single tests and combined
methods using serum pepsinogen and H. pylori antibody tests.
Results: From a large-scale population-based cohort of over 100,000 subjects followed between 1990 and 2004, 497
gastric cancer subjects and 497 matched healthy controls were chosen. The predictive sensitivity and specificity were
low in all single tests and combination methods. The highest predictive sensitivity and specificity were obtained for the
serum PG I/II ratio. The optimal PG I/II cut-off values were 2.5 and 3.0. At a PG I/II cut-off value of 3.0, the sensitivity was
86.9% and the specificity was 39.8%. Even if three biomarkers were combined, the sensitivity was 97.2% and
the specificity was 21.1% when the cut-off values were 3.0 for PG I/II, 70 ng/mL for PG I, and 10.0 U/mL for
H. pylori antibody.
Conclusions: The predictive accuracy of gastric cancer development was low with the serum pepsinogen and
H. pylori antibody tests even if these tests were combined. To adopt these biomarkers for gastric cancer screening, a
high specificity is required. When these tests are adopted for gastric cancer screening, they should be carefully
interpreted with a clear understanding of their limitations.
Keywords: Gastric cancer, Helicobacter pylori antibody, Serum pepsinogen, Receiver operating characteristic
analysis, Cancer screening
Background
Although the incidence of gastric cancer has decreased
worldwide, it remains the fifth most common malignancy
in the world [1]. Gastric cancer remains a heavy burden in
Eastern Asia, South America, and a number of European
countries. However, prevention and screening programs
for gastric cancer particularly at the national level have
not yet been established in most countries. The exceptions
are Korea and Japan where gastric cancer screening pro-
grams have already been introduced [2]. Recently, the
International Agency for Research on Cancer has sug-
gested the establishment of Helicobacter pylori screening
and eradication programs in countries with a high inci-
dence of gastric cancer, taking the local context into con-
sideration [3]. However, the efficacy of the screening
methods used has not yet been evaluated, although they
have been anticipated to reduce gastric cancer incidence.
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Thus, H. pylori screening has not yet been officially intro-
duced either as a national and regional program.
Chronic H. pylori infection plays a central role in the
development of gastric cancer as shown by biological
and epidemiological studies [4]. In a recent study, H.
pylori infection was reported to be associated with 90%
of non-cardia gastric cancer [5]. The associations of
other factors including Cag A, blood type, and lifestyle
with gastric cancer have also been investigated [6–11].
Based on several risk factors related to lifestyle, predic-
tion models for gastric cancer have been developed, and
these models have demonstrated the capability of dis-
criminating high-risk individuals [12]. The serum pep-
sinogen (PG) test can diagnose gastric atrophy, and it
has been used for gastric cancer screening and risk
stratification for gastric cancer with H. pylori antibody
[13–17]. Sasazuki et al. reported that the odds ratio for
gastric cancer development of H. pylori infection with
the gastric atrophy was higher to that of H. pylori infec-
tion and this was lower than that of H. pylori infection
with positive result of CagA [11]. Charvat et al. devel-
oped a prediction model for gastric cancer based on H.
pylori infection and gastric atrophy with the risk factors
related to lifestyle [18]. The strong association between
gastric cancer and these risk factors suggested a high
possibility of predicting gastric cancer incidence in the
high-risk group detected by the serum PG and H. pylori
antibody tests. If the future risk for gastric cancer devel-
opment can be optimally clarified, appropriate prevent-
ive measures can be taken according to individual risks.
These preventive measures can be made more efficient
for gastric cancer screening to accurately target cancer
screening subjects and decrease the screening frequency
of the low-risk group. However, these results are not dir-
ectly connected with primary cancer screening. To adopt
these biomarkers in gastric cancer screening, both sensi-
tivity and specificity should be assessed considering the
balance of benefits and harms.
Receiver operating characteristic (ROC) analysis is a
widely accepted method for selecting an optimal cut-off
value for tests as well as for comparing the sensitivity
and specificity of diagnostic tests [19]. Optimal sensitiv-
ity and specificity can maintain the balance of the bene-
fits and harms of a diagnostic test. A high possibility of
predicting gastric cancer incidence indicates high sensi-
tivity, but the indication of specificity, which identifies
the proportion of subjects without gastric cancer, is still
unclear. A low specificity reportedly indicates a high
false-positive result and this becomes harm in asymp-
tomatic people [20]. Therefore, a high specificity is also
required. However, the predictive sensitivity and specifi-
city of these biomarkers for gastric cancer development
remain unclear. In this study, we evaluated the predict-
ive sensitivity and specificity of the H. pylori antibody
and serum PG tests for predicting gastric cancer devel-




The Japan Public Health Center (JPHC)-based prospect-
ive study on cancer and cardiovascular disease (JPHC
study) was established in 1990. The study population
was defined as all inhabitants in 27 municipalities under
9 public health centers. The study population and design
of the JPHC study have been described in detail else-
where [11]. As a whole, a population-based cohort of
61,009 men and 62,567 women was identified and
followed from January 1, 1990 to December 31, 2004.
Blood sample was provided voluntarily by these subjects
during their health check-ups and was collected from
1990 to 1995. Although a questionnaire survey was per-
formed at their health check-ups, there was no question
related to medicines for gastric diseases which they were
taking. Newly diagnosed cases of cancer were collected
through local major hospitals and local cancer registries.
This study was approved by the Institutional Review
Board of the National Cancer Center, Japan (Approval
number: 2001-013, 14-038). Written informed consent
was obtained from all the participants in the JPHC study.
Laboratory data
The level of IgG antibodies to H. pylori was measured
using a direct ELISA kit (E.Plate ‘Eiken’ H. pylori Anti-
body, Eiken Kagaku Co., Ltd., Tokyo, Japan). The serum
levels of PG I and II were measured by two-step enzyme
immunoassay using commercial kits (E.Plate ‘Eiken’
Pepsinogen I and Pepsinogen II Eiken Kagaku Co., Ltd.).
All measurements were performed by a person blinded
to the study. The levels of PG I, PG II, PG I/II, and H.
pylori antibody were used for diagnosing and predicting
gastric cancer development. In Japan, a combination of
PG I, PG I/II, and H. pylori antibody measurements has
been a commonly used method for stratifying the risk of
gastric cancer. PG I ≤ 70 ng/mL and PG I/II ≤ 3.0 indi-
cate chronic atrophic gastritis. H. pylori infection was
classified as positive when the H. pylori antibody titer
was ≥ 10 U/mL.
Statistical analysis
ROC analysis was performed following the Hanley and
McNeil’s method. The area under the curve (AUC) indi-
cated diagnostic accuracy and defined the optimal cut-
off points of the diagnostic tests. The AUC and 95%
confidence interval (CI) were estimated and compared
among the different biomarkers or their combination.
When the highest likelihood ratio was obtained, the cut-
off value for sensitivity and specificity was defined as
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optimal. Statistical analysis was performed using STATA
13.0 (STATA, College Station, TX, USA). All test statis-
tics were two-tailed, and p-values < 0.05 were considered
to indicate a statistically significant difference.
Before the main analysis for the prediction of gastric
cancer development, ROC analysis for these biomarkers
was performed to investigate their ability to diagnose H.
pylori infection. H. pylori infection was used for deter-
mining outcome using 2 cut-off values (≥10 U/mL and ≥
5 U/mL) and the AUCs among PG I, PG II, and PG I/II
were compared. Then, gastric cancer was used for deter-
mining predictive outcome and the AUCs among PG I,
PG II, PG I/II, and H. pylori antibody titer were com-
pared. The AUCs were also compared among combin-
ation methods using PG I, PG II, PG I/II, and H. pylori
antibody. Finally, the AUCs were estimated and com-
pared between the commonly used definition of the de-
fined value of a combination method using PG I, PG I/
II, and H. pylori antibody. The subjects were classified
into 4 groups according to the risk for gastric cancer
development based on their levels of serum PG and H.
pylori antibody at enrollment. To discriminate the posi-
tive and negative results, the following standard categor-
ies were used: PG I/II = 3.0, PG I = 70.0 ng/mL, and H.
pylori antibody = 10.0 U/mL. Atrophic gastritis was de-
fined on the basis of the results of a combination of PG
I/II and PG I. Based on these categories, the results were
divided into 4groups. The first group subjects had a
“normal” PG level (negative atrophy) and were negative
for H. pylori antibody (negative H. pylori infection). The
second group subjects had a “normal” PG level and were
positive for H. pylori antibody. The third group subjects
had an “atrophic” PG level and were positive for H.
pylori antibody. The fourth group subjects had an “atro-
phic” PG level and were negative for H. pylori antibody.
Results
Target population
We used the dataset from a nested case-control study
from a large-scale cohort study conducted in Japan (i.e.,
JPHC study) [11]. The procedure used for the selection
of the target population is shown in Fig. 1. Of 97,644
eligible subjects in the JPHC study cohort, 13,467 men
and 23,278 women who donated blood samples at base-
line were included. Cases of gastric cancer were ex-
tracted from the cancer registry for the JPHC study
based on site. Among 1,681 cases with a histologically
proven diagnosis made from 1990 to 2004, plasma at
baseline had been obtained from 512 cases. The case
subjects were selected individuals who were diagnosed
as having gastric cancer for the follow-up periods based
on information from local major hospitals and local can-
cer registries. For the case subjects, control subjects
were selected and matched for sex, age (±3 years), blood
donation date (±2 months), and fasting time at blood
donation (±5 h). One case with a technical error with
the H. pylori antibody measurement and the matched
control were excluded. The dataset included 511 case
subjects and 511 matched control subjects [11]. For this
analysis, 14 case subjects who were diagnosed as having
gastric cancer before the blood donation date and 14
matched control subjects were excluded. A total of 994
subjects (497 case subjects having gastric cancer and 497
healthy control subjects) were used for the ROC analysis
in this study. The proportion of female subjects was
33.6% and the average age at participation in the cohort
Fig. 1 Flow chart for target group selection. In a large-scale cohort
study conducted in Japan (i.e., Japan Public Health Center Study
[JPHC study]), a population-based cohort of 61,009 men and 62,567
women was identified and followed from January 1, 1990 to
December 31, 2004. Of 97,644 eligible subjects in the JPHC study
cohort, 13,467 men and 23,278 women who donated blood samples
at baseline were included. Cases of gastric cancer were extracted
from the cancer registry for the JPHC study based on site. Among
1,681 cases with a histologically proven diagnosis made from 1990
to 2004, plasma at baseline was obtained from 512 cases. One case
with a technical error of H. pylori antibody measurement and the
matched control were excluded. The dataset included 511 case
subjects and 511 matched control subjects. For this analysis, 14 case
subjects who were diagnosed as having gastric cancer before the
blood donation date and 14 matched control subjects were excluded.
Thus, a total of 994 subjects (497 case subjects having gastric cancer
and 497 healthy control subjects) were used for the ROC analysis in
this study
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study was 57.5 ± 7.2 years. The average follow-up years
from the blood donation date to diagnosis date of gastric
cancer for case subjects was 6.1 ± 3.4 years.
ROC analysis
When H. pylori infection was classified as a positive case
at ≥ 10.0 U/mL, the AUC of PG I/II was 0.820 ± 0.023
(95% CI: 0.774-0.865) which was significantly higher
than that of the other biomarkers (p < 0.001, Table 1).
Even if the cut-off value was changed from 10.0 U/mL
to 5.0 U/mL, a similar result was obtained (p < 0.001).
The optimal values of PG I/II were 95.0% for sensitivity
and 54.8% for specificity when the H. pylori antibody
titer was defined as a positive case of H. pylori infection
at ≥ 10 U/mL.
The AUC of gastric cancer development was higher in
PG I/II than in the other biomarkers (Table 1, Fig. 2).
The AUC of gastric cancer development was 0.649 ±
0.017 (95% CI: 0.615-0.683) for PG I/II and 0.574 ±
0.018 (95% CI: 0.538-0.610) for H. pylori antibody. The
optimal cut-off values obtained were 2.5 and 3.0 for PG
I/II. When the cut-off value was 2.5 for PG I/II, the opti-
mal values were 71.2% for sensitivity and 52.5% for spe-
cificity. When the cut-off value was changed to 3.0 for
PG I/II, the optimal values were 86.9% for sensitivity and
39.8% for specificity.
As PG I/II has the highest AUC among the single
tests, the AUCs of PG I/II were compared with those of
the other methods (Table 2). The AUC of PG I/II with
PG I was always higher than that of PG I/II with PG II
or H. pylori antibody. When the cut-off value was de-
fined as 3.0 for PG I/II, the optimal cut-off point was
65.0 ng/mL for PG I and the optimal values were 81.9%
for sensitivity and 42.1% for specificity. The AUC of the
combination of PG I/II and PG I was nearly equal to
that of PG I/II (p = 0.2205).
The predictive sensitivity and specificity of the com-
bination method using PG I/II, PG I, and H. pylori anti-
body were estimated with different titers of H. pylori
antibody from 1.0 to 10.0 U/mL (Table 3). The cut-off
values were defined as 3.0 for PG I/II, 70 ng/mL for PG
I, and 10.0 U/mL for H. pylori antibody. A “normal” PG
level (negative atrophy) and negative for H. pylori
antibody (negative H. pylori infection) were defined as
negative results. At the standard cut-off value, the sensi-
tivity was 97.2% and the specificity was 21.1%. When the
titer was changed from 10.0 to 3.0 U/mL for H. pylori
antibody, the sensitivity increased slightly but the speci-
ficity decreased to half. Thus, with a decrease in the titer
of H. pylori antibody, the AUCs slightly changed. Com-
pared with PG I/II, the AUCs of gastric cancer using the
combined method with the standard cut-off values (PG
I/II = 3.0, PG I = 70.0 ng/mL, and H. pylori antibody =
10.0 U/mL) were nearly equal (Fig. 3). When the PG I/II
value was changed from 3.0 to 2.5 and the PG I value
was changed from 70.0 to 65.0 ng/mL in the combin-
ation method, the AUCs were similar. The AUCs of
gastric cancer development were 0.649 ± 0.017 (95% CI:
0.615-0.683) for PG I/II and 0.622 ± 0.015 (95% CI:
0.593-0.651) for the combination method.
Discussion
The association of various risk factors including Cag A,
blood type, and lifestyle with gastric cancer development
has been investigated, and several risk factors have been
shown to have a strong association [6–11]. Although the
predication model has been developed based on these
results, methods for risk stratification in connection with
gastric cancer screening have not been conclusively
identified [12, 18]. However, the adaptation of the serum
PG and H. pylori antibody tests have been anticipated
because these methods involve simple blood tests [13–
17]. A meta-analysis of prospective cohort studies of
gastric cancer development using the combination
method of H. pylori antibody and serum PG tests with
gastric cancer screening has shown that it is possible to
stratify the background risks of gastric cancer [21]. In
this study, we investigated the best available sensitivity
and specificity of the serum PG and H. pylori antibody
tests for the prediction of gastric cancer development in
connection with cancer screening using ROC analysis.
However, the AUCs were usually low because the sensi-
tivity was relatively high when the specificity became ex-
tremely low. ROC analyses is a graphical technique for
Table 1 Comparison of ROC areas among individual biomarkers
Outcome (Cut-off
value)
ROC area (95% CI)
PG I/II PG I PG II HP
H. pylori infection 0.820 ± 0.023 0.455 ± 0.022 0.186 ± 0.016 -
(HP antibody = 10.0) (0.774–0.865) (0.411–0.499) (0.153–0.217)
H. pylori infection 0.849 ± 0.024 0.478 ± 0.025 0.181 ± 0.018 -
(HP antibody = 5.0) (0.801–0.896) (0.429–0.527) (0.146–0.216)
Gastric cancer 0.649 ± 0.017 0.561 ± 0.011 0.434 ± 0.018 0.574 ± 0.018
(0.615–0.683) (0.526–0.597) (0.400–0.469) (0.538–0.610)
HP Helicobacter pylori, PG pepsinogen, ROC receiver operating characteristic, CI confidence interval
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assessing the ability of a test to discriminate between
those with disease and those without disease [22]. It al-
lows the determination of the cut-off value at which op-
timal sensitivity and specificity can be obtained and
enables the comparison of 2 or more diagnostic tests.
Regarding the interpretation of AUC results, a test with
an area > 0.9 indicates high accuracy, 0.7–0.9 as
moderate accuracy, 0.5–0.7 as low accuracy, and 0.5 as a
chance result [22]. In the present ROC analysis, the
AUCs for all the methods were below 0.7 even if the
highest AUC was obtained when PG I/II was used as a
predictive biomarker for gastric cancer development.
Based on these definitions, the predictive sensitivity
and specificity of gastric cancer development were
found to be low in all single tests and combination
methods using serum PG and H. pylori antibody.
Thus, these biomarkers could not discriminate clearly
between individuals with and without gastric cancer
development in this study.
When the combination method using serum PG and
H. pylori antibody tests was evaluated in this study, a
high sensitivity was obtained; however, the specificity
was low. In a previous study using the same dataset for
a nested case-control study, a strong association between
H. pylori infection, gastric atrophy and gastric cancer de-
velopment was shown. The following odds ratios were
obtained when the risk of gastric cancer development
was compared with the individuals with both negative H.
pylori infection and gastric atrophy: 4.2 (95% CI: 2.2-8.0)
for the individuals with positive H. pylori infection and
negative atrophy; 10.1 (95% CI: 5.6-18.2) for the individ-
uals with both positive H. pylori infection and gastric at-
rophy; 4.9 (95% CI: 2.05-12.1) for the individuals with
negative H. pylori infection and positive gastric atophy
[11]. Similar results were obtained from other studies
that evaluated the association of H. pylori infection, gas-
tric atrophy and gastric cancer development [11, 12, 21].
Although these results confirmed the validity of the
strong association for gastric cancer development, and
the results supported a high sensitivity for the prediction
of gastric cancer development, the possibility of not de-
veloping gastric cancer was not assessed and the specifi-
city was ignored. When a prediction model is adopted in
clinical practice, it is necessary to provide accurate and
discriminating predictions in both situations: with and
without gastric cancer development [23]. Therefore,
specificity is an important indicator particularity in
connection with cancer screening because the target
subjects are asymptomatic people. As low specificity
translate into an increase in the number of unnecessary
examinations, this results in the psychological burden of
mislabeling results [20]. When the specificities were
calculated on the basis of previous studies which evalu-
ated the association between H. pylori infection, gastric
Fig. 2 Comparison of AUCs for gastric cancer development
among single tests using serum PG status and H. pylori
antibody. The AUCs were compared among PG I, PG II, PG I/II,
and H. pylori antibody titer. The AUCs of the following tests
were compared with that of PG I/II (AUC = 0.649 ± 0.017, 95%
CI: 0.615-0.683): a, the AUC of PG I (0.561 ± 0.011, 95% CI:
0.526-0.597) was significantly lower than that of PG I/II (p <
0.001); b, the AUC of PG II (0.434 ± 0.018, 95% CI: 0.400-0.469)
was significantly lower than that of PG I/II (p < 0.001); c, the
AUC of H. pylori antibody (0.574 ± 0.018, 95% CI:0.538- 0.610)
was significantly lower than that of PG I/II (p < 0.001)
Hamashima et al. BMC Cancer  (2017) 17:183 Page 5 of 9
Table 2 Comparison of ROC areas among the combination of 2 biomarkers
PG I/II PG I PG II HP
2.5 ROC area 0.627 ± 0.017 0.619 ± 0.017 0.605 ± 0.018
(95% CI) (0.594–0.661) (0.585–0.652) (0.571–0.639)
Optimal cut-off point 65/60 50 5
Optimal sensitivity 70.2/69.8 71.2 70.8
Optimal specificity 53.7/54.1 52.5 54.3
3.0 ROC area 0.638 ± 0.017 0.618 ± 0.017 0.594 ± 0.018
(95% CI) (0.604–0.672) (0.604–0.672) (0.558–0.629)
Optimal cut-off point 65 50 5.0/6.0
Optimal sensitivity 81.9 83.9 82.9/82.7
Optimal specificity 42.1 39.8 42.5/42.7
3.5 ROC area 0.631 ± 0.018 0.618 ± 0.017 0.584 ± 0.082
(95% CI) (0.597–0.665) (0.604–0.672) (0.548–0.620)
Optimal cut-off point 65 50 5.0/6.0
Optimal sensitivity 88.9 91.0 89.9/89.5
Optimal specificity 31.6 29.2 33.8/34.2
HP Helicobacter pylori, PG pepsinogen, ROC receiver operating characteristic, CI confidence interval
Table 3 Comparison of ROC areas among the combination of 3 biomarkers
HP antibody
values
PG I/II = 3.0 PG I/II = 2.5
PGI = 70 PGI = 65 PGI = 70 PGI = 65
1 ROC area 0.619 ± 0.014 0.623 ± 0.014 0.623 ± 0.015 0.625 ± 0.015
(95% CI) (0.591–0.646) (0.595–0.650) (0.594–0.653) (0.596–0.655)
Sensitivity 99.4 100 99.8 99.8
Specificity 8.7 4.4 4.6 4.6
3 ROC area 0.620 ± 0.014 0.624 ± 0.014 0.630 ± 0.015 0.632 ± 0.015
(95% CI) (0.591–0.648) (0.596–0.652) (0.600–0.660) (0.602–0.662)
Sensitivity 99.0 99.2 98.6 98.6
Specificity 11.9 11.9 12.7 12.7
5 ROC area 0.619 ± 0.015 0.624 ± 0.014 0.633 ± 0.016 0.635 ± 0.016
(95% CI) (0.591–0.648) (0.595–0.652) (0.603–0.665) (0.605–0.666)
Sensitivity 98.4 98.4 97.8 97.8
Specificity 16.9 16.9 17.9 17.7
7 ROC area 0.621 ± 0.015 0.625 ± 0.015 0.634 ± 0.016 0.637 ± 0.016
(95% CI) (0.593–0.650) (0.597–0.654) (0.604–0.664) (0.606–0.667)
Sensitivity 97.4 97.4 96.6 96.6
Specificity 19.1 19.1 20.1 20.1
10 ROC area 0.622 ± 0.015 0.626 ± 0.015 0.636 ± 0.016 0.638 ± 0.016
(95% CI) (0.593–0.651) (0.597–0.655) (0.605–0.667) (0.607–0.669)
Sensitivity 97.2 97.2 96.4 96.4
Specificity 21.1 21.1 22.1 22.1
HP Helicobacter pylori, PG pepsinogen, ROC receiver operating characteristic, CI confidence interval
Negative cases were determined when the HP antibody level was below the defined value and the serum PG level was above the defined value of PG I/II or PG I
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atrophy, and gastric cancer development, similar results
related to sensitivity and specificity were obtained. Based
on previous studies related to gastric cancer screening
[13–15], the predicative sensitivity and specificity of the
combination method using PG I/II, PG I, and H. pylori
antibody with a standard cut-off value were 94.0% and
34.3%, respectively. Even if other risk factors of gastric
cancer were included in the model using PG I/II, PG I,
and H. pylori antibody, the sensitivity and specificity of
gastric cancer development were 96.5% and 28.8%, re-
spectively [18]. Although the basic condition and follow-
up times were different in these studies, the predicative
accuracy of gastric cancer development was consistently
low using the serum PG and H. pylori antibody tests.
These results have not been given attention because of
the lack of a wide perspective in evaluating the balance
of benefits and harms in connection with gastric cancer
screening. Thus, only sensitivity was similarly evaluated
in these studies.
Prognosis was estimated from the risk of future out-
comes in individuals based on their clinical and non-
clinical characteristics. Prediction performance could be
targeted to a high-risk group for cancer screenings and
the use of promotion to encourage participation in the
screenings. In the case of low-dose CT screening for
lung cancer, risk prediction models have been developed
based on different variables including smoking and other
risk factors [24–27]. The AUCs of these models were
0.67 to 0.88 and these models discriminated the risk of
lung cancer adequately. Although H. pylori infection is a
primary cause of gastric cancer development, the serum
PG and H. pylori antibody tests are insufficient in pre-
dicting whether or not an individual has gastric cancer.
The aim of an etiological study is to identify particular
risk factors attributed to the outcomes. On the other
hand, a prediction study provides possible outcomes
based on multiple variables associated with the outcome
regardless of the cause [28]. In the prediction model,
every causal factor is a predictor, but not every predictor
is a necessary cause. Because of the possible confusion
between an etiological study and a prediction model,
biomarkers have been expected to be adopted as cancer
screening methods [29, 30]. An accurate prognostic
model does not provide any benefits and change the be-
haviors of the target population of cancer screening if it
is not generalizable even though it is verified [31]. In
addition, inappropriate use of these biomarkers can lead
to a misunderstanding and mismatched labeling of
individual risks of cancer. In this study, the highest AUC
was obtained in PG I/II, which was also correlated with
H. pylori infection. Although the ability of PG I/II to
discriminate gastric cancer development is limited, there
is another possibility of assessing the appropriate screen-
ing interval. In HPV screening for cervical cancer, the
screening interval can be expanded after a negative re-
sult of HPV testing [32, 33]. The diagnosis of atrophy
has improved by conventional endoscopy, thus it has
been adopted in clinical practice and endoscopic screen-
ing. Nomura et al. have reported that endoscopic
findings correlated well with PG I/II based on a multi-
center prospective study [34]. Hence, endoscopic diag-
nosis should also be investigated for the prediction of
gastric cancer development in connection with gastric
cancer screening. Despite the limitation of PG I/II for
predicting gastric cancer development, further study on
how to effectively utilize it for gastric cancer screening is
advantageous.
This study has several limitations. Firstly, the back-
ground of this study has changed compared with that of
other studies in the 1990s. The participants then were
recruited in the early 1990s for a large-scale cohort
study in Japan. Over the last 2 decades, the incidence of
gastric cancer and the infection rate of H. pylori have
decreased, particularly in younger age groups [35, 36].
Therefore, the present results might not be completely
applicable to the current situation. Secondly, the study
subjects might not be a representative sample of the
whole Japanese population. Our study subjects were
taken from the dataset of a previous nested case-control
study. The subjects were chosen from 97,644 eligible
subjects who participated in the survey and blood dona-
tion. In the previous study, the participants in the health
check-up survey had different socioeconomic statuses
and favorable lifestyle profiles, such as smoking less, par-
ticipating in more physical exercises, and eating more
green vegetables and fruits [37]. Third, we used a case-
control dataset for this analysis. Diagnostic accuracy can
be overestimated if the test is evaluated in a group of
Fig. 3 Comparison of AUCs for gastric cancer development
among PG I/II, and combined tests using serum PG status and
H. pylori antibody. Compared with PG I/II, the AUCs of gastric
cancer using the combined method with the standard cut-off
values (PG I/II = 3.0, PG I = 70.0 ng/mL, and H. pylori antibody =
10.0 U/mL) were nearly equal
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patients already known to have the disease and in
normal patients [38, 39]. The results might also be
overestimated. Fourth, there was no detailed information
regarding the medicine the subjects took for gastric
disease. As the health insurance did not cover H. pylori
eradication during the study period, asymptomatic
people had few opportunities to avail of the program.
Moreover, a proton pump inhibitor might be also af-
fected by misclassification. Finally, we could not com-
pletely exclude individuals with gastric cancer at the
baseline because the baseline survey included general
health check-up, but not endoscopic examination.
Therefore, the predictive sensitivity of gastric cancer de-
velopment might be overestimated.
Conclusions
In conclusion, the predictive accuracy of gastric cancer
development was low with the serum PG and H. pylori
antibody tests even if these tests were combined. To ef-
fectively adopt these biomarkers for gastric cancer
screening, high specificity and sensitivity are required.
When these tests are included for gastric cancer screen-
ing, they should be carefully interpreted in terms of their
limitations. Further study is needed on how to adopt risk
assessment when using these biomarkers and endoscopic
diagnosis in connection with gastric cancer screening.
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